Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for Sept. 23, 2026, at 9 a.m. EDT and will be webcast live. The full press release is available at https://nnw.fm/8dLEZ.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, focuses on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The TD Cowen summit brings together experts to discuss emerging mechanisms in neuropsychiatry. Helus Pharma's participation underscores its commitment to advancing mental health treatments through innovative science. With class-leading data, the company seeks to improve the treatment landscape by providing durable improvements in mental health. Investors and industry watchers will be keen to hear updates on Helus Pharma's clinical programs and strategic direction.
This news is significant as it highlights the growing interest in novel psychiatric treatments. Mental health disorders affect millions worldwide, and current therapies often fall short for many patients. Helus Pharma's NSAs represent a potential new class of medications that could offer hope where existing options have failed. The company's progress with HLP003 and HLP004 will be closely monitored, especially given the FDA's Breakthrough Therapy Designation for HLP003, which may expedite its development and review.
The announcement was disseminated by NetworkNewsWire ("NNW"), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement. These services help companies like Helus Pharma reach a wide audience of investors and journalists.
For investors, the summit could provide insights into Helus Pharma's pipeline and market potential. The company's focus on serotonergic agonists aligns with a broader trend in neuroscience toward targeting neuroplasticity to treat mood disorders. If successful, Helus Pharma's therapies could address a multi-billion-dollar market. However, clinical development remains risky, and timelines can be unpredictable. The fireside chat may offer clues about upcoming milestones and regulatory pathways.
Helus Pharma's participation in the TD Cowen summit also signals its engagement with the investment community. As a clinical-stage company, maintaining visibility and credibility is crucial for fundraising and partnerships. The event provides a platform to articulate its vision and differentiate its approach. With mental health increasingly in the public spotlight, innovations like NSAs could attract significant attention. The webcast will be accessible live, allowing stakeholders to tune in. For updates, follow the company on social media and visit its website. In summary, Helus Pharma's CEO appearance at a leading neuropsychiatry summit highlights the company's progress and the potential of its novel treatments to transform mental health care.
